NASDAQ: COEPCoeptis Therapeutics Holdings Inc Stock
$9.92+0.95 (+10.59%)
Updated Apr 29, 2025
COEP Price
$9.92
Fair Value Price
N/A
Market Cap
$33.38M
52 Week Low
$2.31
52 Week High
$13.70
P/E
-1.76x
P/B
10.48x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.81M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.58
Operating Cash Flow
-$7M
Beta
0.33
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine COEP's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
COEP
Ranked#261 of 462
Ranked#261 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important COEP news, forecast changes, insider trades & much more!
COEP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how COEP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
COEP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
COEP is poor value based on its book value relative to its share price (10.48x), compared to the US Biotechnology industry average (4.37x)
P/B vs Industry Valuation
COEP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more COEP due diligence checks available for Premium users.
Valuation
COEP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.76x
Industry
-158.75x
Market
29.19x
COEP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.48x
Industry
4.37x
COEP is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
COEP's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.9M
Profit Margin
0%
COEP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$8.9M
Liabilities
$5.0M
Debt to equity
1.58
COEP's short-term liabilities ($4.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COEP's short-term assets ($1.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COEP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
COEP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.4M
Investing
$100.0k
Financing
$732.0k
COEP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
COEP vs Biotech Stocks
Coeptis Therapeutics Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.